Since joining Kirkland, Sierra has been involved in the following representative matters:
- China International Capital Corporation Hong Kong Securities Limited, in connection with the new H-share placing of ImmuneOnco Biopharmaceuticals (HKSE: 1541). The gross proceeds received by ImmuneOnco Biopharmaceuticals from the H-Share Placing are approximately HK$234 million
- Fangzhou Inc. (HKSE: 6086), the largest online chronic disease management platform in China in terms of average monthly active users in 2023, on the global offering and listing on the Hong Kong Stock Exchange on July 9, 2024
- The joint sponsors and underwriters on the global offering and listing of ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (HKSE: 1541), a leading science-driven biotechnology company dedicated to the development of immuno-oncology therapies in China, on the Hong Kong Stock Exchange on September 5, 2023
- Arrail Group Limited (HKSE: 6639), the largest dental services provider in the premium private dental service market in China by revenue, on its global offering and listing on the Hong Kong Stock Exchange on March 22, 2022
- Joy Spreader Group Inc. (HKSE: 6988), a leading China-based marketing technology company, on the raising of approximately US$77.5 million by way of top-up placing of existing shares. Goldman Sachs was the sole placing agent
Prior to joining Kirkland, Sierra was involved in the following representative matters:
Life Sciences
- Kangji Medical Holdings Limited (HKSE: 9997) on its HK$3.1 billion (approximately US$404 million) IPO on the Hong Kong Stock Exchange as Hong Kong and U.S. legal counsel. Goldman Sachs (Asia) LLC, CLSA Capital Markets Limited and Merrill Lynch Far East Limited acted as joint sponsors for the transaction
- Ascletis Pharma, Inc., in connection with its US$457 million IPO on the Hong Kong Stock Exchange. Ascletis is the first biotechnology company successfully listed on the HKEx since HKEx’s new rules took effect on April 30, 2018, which opened the door to pre-revenue biotechnology companies
Other Equity Capital Markets
- Clover Biopharmaceuticals, a global clinical-stage biotechnology company developing transformative biologics as vaccines and therapeutics for the world’s most debilitating diseases, on the successful completion of an oversubscribed US$230 million Series C financing. The financing round was co-led by GL Ventures and Temasek, with participation from Oceanpine Capital, OrbiMed and existing investor Delos Capital
- Joy Spreader Interactive Technology. Ltd (HKSE: 6988) in connection with its IPO on the Hong Kong Stock Exchange. The offering raised net proceeds of HK$1.56 billion (approximately US$200 million). Joy Spreader is one of the leading performance-based we-media marketing service providers in China
- Hilong Holding Limited, a leading integrated oilfield equipment and service provider operating in the PRC and international markets, in an offer to purchase its outstanding 7.25% senior notes due 2020, subject to a maximum acceptance amount and featuring an allocation priority in a concurrent new notes issuance, and the concurrent new issuance of 8.25% senior notes due 2022
- BabyTree Group in connection with its US$218 million IPO on the Hong Kong Stock Exchange. BabyTree Group is one of the largest and most active M&C-focused community-based platforms in China
- Shandong Gold Mining Co., Ltd., an A-share listed company, in connection with its US$594 million offering and listing of H-Shares on the Hong Kong Stock Exchange. Shandong Gold is engaged in the mining and smelting of gold
- China International Capital Corporation Hong Kong Securities Limited, China Merchants Securities (HK) Co., Limited, CCB International Capital Limited and ABCI Capital Limited as joint sponsors and underwriters in connection with Guangzhou Rural Commercial Bank’s initial public offering on the Stock Exchange of Hong Kong Main Board
- Sinco Pharmaceuticals Holdings Limited, in connection with its initial public offering on the Hong Kong Stock Exchange. Proceeds: HK$262.3 million (US$33.8 million)
- China Hengshi Foundation Company Limited, in connection with its initial public offering on the Hong Kong Stock Exchange. Proceeds: HK$320 million (US$41.6 million)
- CAR Inc., in connection with its initial public offering on the Hong Kong Stock Exchange. Proceeds: HK$3.4 billion (US$444.7 million)
